

SHEET 1 of 3

Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
29342/36212Serial No.  
09/558,9Applicant  
Emmick et al.Filing Date  
04/26/00Group  
1646**INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)

RECEIVED  
JUL 10 2001  
TECH CENTER 1600/2600**U.S. PATENT DOCUMENTS**

| *Examiner Initials | Document Number | Issue Date | Name             | Class | Subclass | Filing Date If Appropriate |
|--------------------|-----------------|------------|------------------|-------|----------|----------------------------|
| W/S                | 4,931,445       | 06/05/90   | Goldstein et al. | 514   | 252      |                            |
|                    | 5,702,936       | 12/30/97   | Beavo et al.     | 435   | 196      |                            |
|                    | 5,859,006       | 01/12/99   | Daugan           | 514   | 249      |                            |
|                    | 5,981,527       | 11/09/99   | Daugan et al.    | 514   | 250      |                            |
|                    | 5,985,326       | 11/16/99   | Butler           | 424   | 484      |                            |
| W/S                | 6,001,847       | 12/14/99   | Daugan et al.    | 514   | 287      |                            |

**FOREIGN PATENT DOCUMENTS**

| *Examiner Initials | Document Number | Publication Date | Country | Class | Subclass | Translation       |    |
|--------------------|-----------------|------------------|---------|-------|----------|-------------------|----|
|                    |                 |                  |         |       |          | Yes               | No |
| W/S                | WO 96/32003     | 10.96            |         |       |          |                   |    |
|                    | WO 97/03675     | 06.02.97         | PCT     | A61K  | 31/495   |                   |    |
|                    | WO 99/59584     | 25.11.99         | PCT     | A61K  | 31/415   |                   |    |
|                    | WO 00/20033     | 13.04.00         | PCT     | A61K  | 41/00    | x (abstract only) |    |
|                    | WO 97/43287     | 20.11.97         | PCT     | C07D  | 471/04   |                   |    |
|                    | WO 00/15639     | 23.03.00         | PCT     | C07D  | 471/04   |                   |    |
| W/S                | 2,020,630       | 1991/01/08       | CA      | C07D  | 487/04   | X                 |    |
|                    |                 |                  |         |       |          |                   |    |

EXAMINER

DATE CONSIDERED

08/01/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
29342/36212Serial No.  
09/558,912Applicant  
Emmick et al.Filing Date  
04/26/00Group  
1646

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED  
JUL 10 2001  
TECH CENTER 600/2400

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)


|     |  |  |
|-----|--|--|
| M/3 |  | Physicians' Desk Reference, 53 Edition, 1999, pp. 2424-2427.   |
|     |  | Rosen et al., The international index of erectile function (IIEF): A multidimensional scale for assessment of erectile dysfunction, <i>Urology</i> , 49(6), pp. 822-830 (1997).  |
|     |  | K.J. Murray, Phosphodiesterase PDE V <sub>A</sub> inhibitors, <i>DN&amp;P</i> , 6(3), pp. 150-156 (1993).  |
|     |  | A. Taher et al. <i>J. Urology</i> , 149:285a, AUA Eighty-Eighth Annual Meeting, May, 1993.   |
|     |  | M. Boolell et al., Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction, <i>Int. J. of Impotence Res.</i> , 8, pp. 47-52 (1996).   |
|     |  | A.M. Martel et al., Treatment of erectile dysfunction phosphodiesterase V inhibitor, <i>Drugs of the Future</i> , 22(2), pp. 138-143 (1997).   |
|     |  | J.N. Wells et al., Cyclic nucleotide, phosphodiesterase activities of pig coronary arteries, <i>Biochim. Biophys. Acta</i> , 384, pp. 430-442 (1975).  |
|     |  | A. Sitaramayya et al., On the mechanism of light activation of retinal rod outer segments cyclic GMP phosphodiesterase (light activation-influence of bleached rhodopsin and KF-deinhibition), <i>Exp. Eye Res.</i> , 25, pp. 163-169 (1977).                      |
|     |  | N. Virmaux et al., Proteins of bovine retinal outer segments: electrophoresis on polyacrylamide gels in the presence of sodium dodecyl sulfate, <i>FEBS Letters</i> , 12(6), pp. 325-328 (1971).   |
|     |  | K. Loughney et al., Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases, <i>The Journal of Biological Chemistry</i> , 271(2), pp. 796-806 (1996).                         |
| M/2 |  | Y.C. Cheng et al., Relationship between the inhibition constant (K <sub>i</sub> ) and the concentration of inhibitor which causes 50 per cent [sic] inhibition (I <sub>50</sub> ) of an enzymatic reaction, <i>Biochem. Pharmacol.</i> , 22, pp. 3099-3108 (1973). |

EXAMINER

DATE CONSIDERED

08/09/01

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 (Modified)

U.S. Department of Commerce  
Patent and Trademark OfficeAtty. Docket No.  
29342/36212Serial No.  
09/558,911Applicant  
Emmick et al.Filing Date  
04/26/00Group  
1646

## INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

RECEIVED  
JUL 10 2001  
TECH CENTER 1600/2800

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

|     |   |
|-----|---|
| MP2 | D. Webb et al., Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist, <i>Amer. J. of Cardiology</i> , 83(5A), pp. 21C-28C (1999). |
|     | V. Price et al., Expression of heterologous proteins in <i>Saccharomyces cerevisiae</i> using the ADH2 promoter, <i>Methods in Enzymology</i> , 185, pp. 308-318 (1990).  |
|     | H. Shichi et al., Biochemistry of visual pigments, <i>J. Biol. Chem.</i> , 244(3), pp. 529-536 (1969).  |
|     | Goldenberg, "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction," <i>Clinical therapeutics</i> , 20, No. 6, pp. 1033-1048 (1998).  |
|     | Israel, "Viagra: The first oral treatment for impotence," <i>The Pharmaceutical Journal</i> , 261, pp. 164-165 (1998).  |
|     | C. Conti et al., <i>Amer. J. of Cardiology</i> , 83(5A), 29C-34C (March 4, 1999).   |
|     | I. Goldstein et al., <i>The New England Journal of Medicine</i> , Vol. 338, No. 20, pp. 1397-1404 (1998).   |
|     | S.A. Ballard et al., <i>The Journal of Urology</i> , Vol. 159, pp. 2164-2171 (1998).  |
|     | Product insert, VIAGRA® Tablets (2000).   |
| WB  | Gennaro et al., Ed., Remington: The Science and Practice of Pharmacy, 19th Ed., p. 806 (1995).  |
|     |   |

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.